PUBLIC COMPANY
save$VORVor Biopharma Inc.
$VOR19.32-3.83%Boston, MA, USupdated 4d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Vor pays RemeGen $10M for long-acting addition to autoimmune pipelineVor Bio is paying RemeGen $10 million upfront in cash for rights to RC298 outside Greater China, adding a long-acting drug candidate to its BAFF/APRIL franchise.fiercebiotech · 5d ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that